AI is transforming life sciences, but not without exposing long-standing structural weaknesses. From fragmented data to interdisciplinary silos and regulatory pressure, success depends on readiness, not ambition.
The life sciences sector has long struggled with an imbalance between the volume of its data and its utility. Despite collecting vast amounts of information from clinical trials, omics platforms, real-world evidence, diagnostic imaging, claims systems, and patient records, organisations have often lacked the means to derive coherent, cross-functional insights. AI has emerged as a potential solution, but its effectiveness hinges on the very structural issues that have historically constrained progress. To gain traction, AI must address the data fragmentation, organisational complexity, and compliance obligations that define the sector.
Joe Paxton, Senior Vice President of Life Sciences at CitiusTech, describes AI not as a disruptive force from the outside but as a necessary response to deep internal constraints. “AI is a compelling reason to really get your company’s data sets and data understanding in line,” he explains. “If you do not have the data to get the outcomes you are looking for, you are going to get poor outcomes. Executives are moving quickly to ensure they have a plan to address this.”
For organisations that have historically been reluctant to restructure around data, AI has become a tipping point. It is no longer possible to deliver value with outdated pipelines and fragmented infrastructure. As models become more complex and ambitions grow larger, the requirements of integration, explainability, and validation become unavoidable. AI is not merely a tool; it is a test of organisational maturity.
Data unification as a prerequisite for AI readiness
In life sciences, the problem is rarely the absence of data. The challenge lies in reconciling multiple formats, sources, and standards across research, development, regulatory, and commercial functions. These silos not only limit operational efficiency but also introduce risk. Models built in isolation from this broader context are more likely to fail.
Paxton is clear that organisations achieving real progress are those that address this complexity head-on. “What we see among companies making real headway is that they are not just deploying models, they are rebuilding the data foundations required to make those models useful,” he says. “That includes ingesting imaging data, omics data, and social factors, and mapping them into interoperable formats that are fit for purpose.”
When large language models are introduced, these issues are further magnified. The cost of using generic or misaligned data becomes prohibitive. With the increasing use of external datasets, often licenced at significant cost, the need to verify the fitness of those datasets for specific scientific purposes has never been greater.
This is no longer just an engineering concern; it has become a broader issue. It has become a strategic priority. “These models are only useful if you are selecting the right data to train and interrogate them,” Paxton explains. “That is why we are seeing a greater focus on tools that help scientists make sure they are using the right data for their study.”
The consequences of poor data quality extend beyond failed models. They jeopardise regulatory compliance, clinical efficacy, and market credibility. With more teams relying on AI-driven analysis for evidence generation, indication expansion, and portfolio optimisation, the margin for error is narrowing. The organisations best positioned to benefit from AI are not necessarily those with the most sophisticated models; they are those with the most precise understanding of their own data landscape.
From pilots to platforms: the leap to enterprise scale
Early success with AI often begins at the edge of the business, with a single team, a single dataset, and a single model. The real challenge comes when attempting to scale that capability across the entire enterprise. In life sciences, this means aligning R&D, clinical development, commercial operations, and pharmacovigilance on a single technical and operational architecture. That alignment is rare.
Paxton acknowledges that the shift from pilot to platform is where many initiatives stall. “It depends on the company,” he says. “Some are making the investment. Some are still experimenting. But where we see real success is where the platform has been designed from the start to be scalable, to be dynamic, and to bring in multiple different data sets.”
This design principle also informs infrastructure choices. Many organisations have now standardised hyperscalers such as AWS, Azure, or GCP to provide the elasticity and compute power required for AI workloads. But Paxton is quick to note that infrastructure alone does not deliver transformation. Without interoperability, trust, and user-level alignment, even the most potent platforms remain underutilised.
The integration of clinical and commercial datasets is a key example. Historically, these domains have been managed in isolation, each with its own tools, logic, and priorities. AI requires them to converge. Whether the goal is predictive trial design, cohort segmentation, or post-market surveillance, success depends on access to a unified, validated dataset. Organisations that fail to connect these systems will continue to operate in silos, regardless of how advanced their models appear on paper.
Compliance is a foundation, not a constraint
No sector is more constrained by compliance than life sciences, where patient safety, data privacy, and regulatory oversight shape every decision. But treating compliance as a barrier to innovation is a false narrative. Done well, it becomes a driver of quality and a source of competitive differentiation.
“There is no grey area,” Paxton explains. “You must meet the standards, HIPAA, GDPR, and CFR Part 11. It is non-negotiable.” The best-performing companies do not wait to be told how to comply. They build AI strategies around compliance from the outset, incorporating auditability, traceability, and explainability into their core workflows.
Regulatory expectations are also evolving rapidly. Agencies are beginning to explore formal guidelines for AI validation, including model risk classification, performance testing, and audit mechanisms. While these frameworks are still emerging, life sciences companies already have the tools and cultural practices to lead. Existing processes around clinical trials, safety monitoring, and quality management can be extended to AI with the correct design principles.
Paxton also identifies governance as a growing area of focus. “AI governance is something that should be incorporated just like data governance,” he says. “If you are in life sciences, you know that you must ensure that your products are safe and effective.” This includes not only ensuring fairness and bias mitigation but also the ability to explain and defend decisions to regulators, physicians, and patients.
For organisations able to build trustworthy systems, the rewards are significant. Regulators are not opposed to innovation, but they will not compromise on transparency. Those who can demonstrate robust oversight will find it easier to launch, scale, and license new AI-enabled capabilities.
People remain the anchor for meaningful transformation
Perhaps the most overlooked aspect of AI deployment is the continued importance of human judgment. While the promise of automation is enticing, particularly in high-cost and high-latency domains, Paxton insists that people, not machines, must remain at the centre of decision-making.
“The patient is still the centre,” Paxton says. “The doctor and the clinician are very important to decision making. AI should be the enabler, not the answer. That distinction is critical. It is tempting to treat AI as a replacement for expert knowledge, but this shortcut leads to brittle systems and eroded trust.”
Instead, Paxton envisions a future where AI becomes deeply embedded in clinical workflows, supporting, guiding, and accelerating processes rather than replacing them. From personalised treatment planning to adaptive trial design, the emphasis is on augmentation, not automation.
What excites him most is the convergence of data domains and modelling techniques. As barriers between imaging, omics, EHRs, and social data fall, the potential for multidimensional analysis expands. Intelligent platforms can now help researchers select relevant data, streamline ingestion, and generate insights that are both rigorous and reproducible. This not only accelerates discovery but also improves the relevance and quality of outputs across the value chain.
At the same time, the speed of change introduces new responsibilities. Paxton warns against underestimating the velocity at which AI is being adopted. What once took a decade to shift now moves in cycles of two or three years. This places pressure not only on technical infrastructure but also on cultural readiness, training, and executive alignment.
Organisations that succeed will be those that align AI ambitions with operational capability, governance frameworks, and human-centred design. Those who chase capability without context will find themselves overwhelmed by complexity.
